1900 9th Avenue, Suite 1100
Corixa is a biopharmaceutical company developing oncology and immunology products that manage human diseases. On June 30, 2003, Corixa announced that the FDA approved BEXXAR for the treatment of patients with CD20 positive,
follicular, NHL, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy.
Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. In addition
to BEXXAR, Corixa currently has multiple programs in clinical development, including several product candidates that have advanced to and through late stage clinical trials. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are Powered by
Corixa(tm) technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, with additional operations in Hamilton, Mont., and South San Francisco. For more information, please visit Corixa's Web site at www.corixa.com.
- Steven Gillis, Ph.D., Chairman and Chief Executive Officer
- Michelle Burris, Senior Vice President and Chief Financial Officer
- David Fanning, Senior Vice President and Chief Operating Officer
Last Updated: 10-18-04